NASDAQ:POAI Predictive Oncology (POAI) Stock Price, News & Analysis $1.38 -0.49 (-26.20%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.21▼$1.5550-Day Range$0.89▼$2.0952-Week Range$0.89▼$5.94Volume5.98 million shsAverage Volume1.98 million shsMarket Capitalization$5.66 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Predictive Oncology alerts: Email Address Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Predictive Oncology Stock (NASDAQ:POAI)Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota.Read More POAI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart POAI Stock News HeadlinesJuly 26 at 8:00 AM | globenewswire.comPredictive Oncology Announces Exercise of Warrants for $1.26 Million Gross ProceedsJuly 25 at 10:50 PM | msn.comWhy Predicitive Oncology Stock Is SoaringJuly 26, 2024 | WealthPress (Ad)New trading system called MSFT, NVDA & MSFTLook 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.July 25 at 6:17 PM | investorplace.comWhy Is Predictive Oncology (POAI) Stock Up 70% Today?July 25 at 8:20 AM | finance.yahoo.comPredictive Maintenance Market to Witness 31.2% CAGR Growth | SkyQuest TechnologyJuly 25 at 7:00 AM | globenewswire.comPredictive Oncology Enters Biomarker Discovery Market After Successful Retrospective Ovarian Cancer Study Yields Compelling ResultsJuly 20, 2024 | americanbankingnews.comPredictive Oncology (NASDAQ:POAI) Stock Price Passes Below 200-Day Moving Average of $2.13June 11, 2024 | globenewswire.comPredictive Oncology Develops Novel Stem Cell Expression System for the Production of Functional and Stable G-Protein Coupled Receptors (GPCRs)July 26, 2024 | WealthPress (Ad)New trading system called MSFT, NVDA & MSFTLook 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.June 4, 2024 | globenewswire.comPredictive Oncology Launches Novel 3D Cell Technology to Accelerate Cancer Therapeutic Drug DiscoveryMay 29, 2024 | globenewswire.comPredictive Oncology Announces CEO Raymond Vennare to Present at the BIO International Convention 2024May 28, 2024 | marketwatch.comPredictive Oncology Shares Gain 33% After Ovarian Cancer AI StudyMay 28, 2024 | msn.comWhy Predictive Oncology (POAI) Stock Is SkyrocketingMay 28, 2024 | globenewswire.comPredictive Oncology Announces Positive Results from Ovarian Cancer Study with UPMC Magee-Womens Hospital to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingMay 16, 2024 | uk.finance.yahoo.comQ1 2024 Predictive Oncology Inc Earnings CallMay 16, 2024 | finance.yahoo.comPredictive Oncology Inc (POAI) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...May 15, 2024 | finanznachrichten.dePredictive Oncology Inc.: Predictive Oncology Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 15, 2024 | investorplace.comPOAI Stock Earnings: Predictive Oncology Reported Results for Q1 2024See More Headlines Receive POAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Predictive Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical appliances & supplies Sub-IndustryN/A Current SymbolNASDAQ:POAI CUSIPN/A CIK1446159 Webwww.precisiontherapeutics.com Phone(651) 389-4800FaxN/AEmployees34Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,980,000.00 Net Margins-754.13% Pretax Margin-754.13% Return on Equity-151.51% Return on Assets-91.35% Debt Debt-to-Equity RatioN/A Current Ratio1.45 Quick Ratio1.35 Sales & Book Value Annual Sales$1.78 million Price / Sales3.18 Cash FlowN/A Price / Cash FlowN/A Book Value$2.04 per share Price / Book0.68Miscellaneous Outstanding Shares4,100,000Free Float3,961,000Market Cap$5.66 million OptionableNot Optionable Beta1.15 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Raymond F. Vennare (Age 71)CEO & Chairman Comp: $525kMr. Joshua Blacher M.B.A. (Age 51)Interim Chief Financial Officer Ms. Theresa FergusonSenior Director of MarketingDr. Lawrence J. DeLucas D.ScO.D, Ph.D., Senior Vice President of BiologicsDr. Arlette H. Uihlein FCAPM.D., Senior VP of Translational Medicine & Drug Discovery and Medical DirectorKey CompetitorsHeart Test LaboratoriesNASDAQ:HSCSNanoVibronixNASDAQ:NAOVLogicMarkNASDAQ:LGMKBone BiologicsNASDAQ:BBLGSientraNASDAQ:SIENQView All CompetitorsInsidersCharles Lee Sr Nuzum SrSold 10,000 sharesTotal: $30,400.00 ($3.04/share)View All Insider Transactions POAI Stock Analysis - Frequently Asked Questions How have POAI shares performed this year? Predictive Oncology's stock was trading at $3.29 on January 1st, 2024. Since then, POAI stock has decreased by 58.1% and is now trading at $1.38. View the best growth stocks for 2024 here. How were Predictive Oncology's earnings last quarter? Predictive Oncology Inc. (NASDAQ:POAI) posted its quarterly earnings data on Tuesday, May, 14th. The medical instruments supplier reported ($1.04) EPS for the quarter. The medical instruments supplier earned $0.42 million during the quarter. Predictive Oncology had a negative net margin of 754.13% and a negative trailing twelve-month return on equity of 151.51%. When did Predictive Oncology's stock split? Shares of Predictive Oncology reverse split on Monday, April 24th 2023. The 1-20 reverse split was announced on Monday, April 24th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 24th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Predictive Oncology? Shares of POAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Predictive Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Predictive Oncology investors own include NVIDIA (NVDA), OPKO Health (OPK), Enphase Energy (ENPH), Inovio Pharmaceuticals (INO), Overstock.com (OSTK), Riot Platforms (RIOT) and AcelRx Pharmaceuticals (ACRX). This page (NASDAQ:POAI) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Predictive Oncology Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Predictive Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.